| pubmed-article:18594006 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18594006 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:18594006 | lifeskim:mentions | umls-concept:C0034595 | lld:lifeskim |
| pubmed-article:18594006 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:18594006 | lifeskim:mentions | umls-concept:C0162388 | lld:lifeskim |
| pubmed-article:18594006 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:18594006 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:18594006 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:18594006 | pubmed:dateCreated | 2008-7-2 | lld:pubmed |
| pubmed-article:18594006 | pubmed:abstractText | Exposing human tumor cells to sublethal doses of external beam radiation up-regulates expression of tumor antigen and accessory molecules, rendering tumor cells more susceptible to killing by antigen-specific CTLs. This study explored the possibility that exposure to palliative doses of a radiopharmaceutical agent could alter the phenotype of tumor cells to render them more susceptible to T cell-mediated killing. | lld:pubmed |
| pubmed-article:18594006 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18594006 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594006 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18594006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594006 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18594006 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18594006 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:SchlomJeffrey... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:CamphausenKev... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:CarrasquilloJ... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:PaikChang HCH | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:WansleyElizab... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:HodgeJames... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:ChakrabortyMa... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:YuSarahS | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:GoeckelerWill... | lld:pubmed |
| pubmed-article:18594006 | pubmed:author | pubmed-author:BeckerMichael... | lld:pubmed |
| pubmed-article:18594006 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18594006 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18594006 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:18594006 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18594006 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18594006 | pubmed:pagination | 4241-9 | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:meshHeading | pubmed-meshheading:18594006... | lld:pubmed |
| pubmed-article:18594006 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18594006 | pubmed:articleTitle | The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. | lld:pubmed |
| pubmed-article:18594006 | pubmed:affiliation | Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. | lld:pubmed |
| pubmed-article:18594006 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18594006 | pubmed:publicationType | Research Support, N.I.H., Intramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18594006 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18594006 | lld:pubmed |
